Adebrelimab + Chemo with Radiation for Extensive-Stage SCLC
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer (cancer that has spread outside one lung or to other parts of the body).
- You must not have had any chemotherapy or other treatments specifically for this stage of cancer before.
- Your cancer must be measurable on scans, with no more than 5 spots (tumors) that have spread.
- You need to be in generally good health, able to walk and care for yourself (ECOG score 0-2), with a life expectancy of at least 3 months.
- Your major organs (heart, lungs, liver, kidneys, bone marrow) must be working well enough, based on blood tests and heart ultrasound.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This trial tests a combination of two drugs (adebrelimab and etoposide capsules) as maintenance therapy for people with extensive-stage small cell lung cancer who have not progressed after initial treatment. It may help extend the time before the cancer grows back.
This study tests a new immunotherapy drug (adebrelimab) combined with standard chemotherapy and radiation for people with a large, stage III lung cancer that cannot be surgically removed. The goal is to see if adding this drug helps shrink or control the cancer better than treatment without it.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for limited-stage small cell lung cancer. After the initial treatment, the drug is continued to help keep the cancer from coming back.
This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.